KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Vertex Pharmaceuticals (VRTX) over the last 15 years, with Q4 2025 value amounting to $139.9 million.

  • Vertex Pharmaceuticals' Tax Provisions fell 3740.49% to $139.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $690.0 million, marking a year-over-year decrease of 1200.1%. This contributed to the annual value of $690.0 million for FY2025, which is 1200.1% down from last year.
  • According to the latest figures from Q4 2025, Vertex Pharmaceuticals' Tax Provisions is $139.9 million, which was down 3740.49% from $215.9 million recorded in Q3 2025.
  • Vertex Pharmaceuticals' Tax Provisions' 5-year high stood at $257.9 million during Q4 2022, with a 5-year trough of -$111.2 million in Q2 2021.
  • Its 5-year average for Tax Provisions is $176.6 million, with a median of $192.2 million in 2022.
  • In the last 5 years, Vertex Pharmaceuticals' Tax Provisions plummeted by 78960.0% in 2021 and then skyrocketed by 29235.61% in 2022.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' Tax Provisions stood at $100.8 million in 2021, then skyrocketed by 155.85% to $257.9 million in 2022, then plummeted by 30.67% to $178.8 million in 2023, then increased by 25.0% to $223.5 million in 2024, then tumbled by 37.4% to $139.9 million in 2025.
  • Its last three reported values are $139.9 million in Q4 2025, $215.9 million for Q3 2025, and $250.1 million during Q2 2025.